Managed Healthcare Executive interviewed Joe Fuhr, Professor Emeritus of Economics, Widener University

Managed Healthcare Executive interviewed Joe Fuhr, Professor Emeritus of economics at Widener University in Chester, PA on evolving drug pricing issues in Washington involving generics and biosimilars.
Fuhr discusses the recent Medicare Part B changes regarding biosimilars and their coding and prices. Fuhr believes some companies may not want to enter a market where they have no control over price. He also contrasts generics vs. biosimilars by saying, “Also, the biologic market is different from the generic market in that there are no wraparound services provided for generics, which are generally pills. For biologics, not only must the medicine be developed but these medicines are injected so that devices must be developed, and thus a biosimilar company would have little incentive to develop a superior device since it will be paid the same as every other firm.”
Click here to read the entire interview.

Become a Member

Whether you have an established practice, you’re fresh out of your fellowship, or you’re a hospital-based rheumatologist considering private practice, United Rheumatology offers the resources and services you need to advance your career and your clinic.

Name(Required)

Find a UR Rheumatologist Near Me

© 2023 United Rheumatology